Background
Colorectal cancer (CRC) is among the most prevalent malignant tumors and accounts for nearly 10% of annual cancer diagnoses globally. Additionally, CRC is the main identifiable cause of cancer-related deaths globally [
1,
2]. Recent advancements in surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy, and multimodal therapy have led to significant progress in CRC treatment. However, the overall survival of patients with advanced CRC remains poor. Tumor-associated recurrence and metastasis are the main causes of death in CRC patients [
3]. Consequently, there is an urgent need to identify practical and reliable biomarkers and explore the underlying disease mechanisms to aid in CRC diagnosis and therapy.
Long non-coding RNAs (lncRNAs), which are RNA transcription products comprised of more than 200 nucleotides, cannot encode proteins. LncRNAs regulate gene expression and function at the transcriptional, translational, and post-translational levels [
4]. Compelling evidence shows that lncRNAs are largely associated with the occurrence and development of numerous diseases including tumors, metabolic disorders, and cardiovascular diseases [
5]. Recent studies demonstrate the role of lncRNAs in tumor pathogenesis, including cell proliferation, migration, invasion, epithelial-mesenchymal transition (EMT), apoptosis, drug resistance, and immune escape [
6,
7]. Notably, lncRNA GAS6-AS1 is the antisense transcriptional RNA of growth arrest specific 6 (GAS6). GAS6-AS1 regulated GAS6 level during transcription or translation phase, thereby boosting the AXL receptor tyrosine kinase (AXL) level and stimulating AXL signal. GAS6 and GAS6-AS1 are both involved in the pathogenesis of cancers [
8]. Although most studies revealed that GAS6-AS1 functions as an oncogene and was highly expressed in gastric, hepatocellular, breast cancers and acute myeloid leukemia (AML), there were studies found that low GAS6-AS1 expression was associated with poor prognosis in lung cancer patients and that GAS6-AS1 overexpression inhibited lung adenocarcinoma progression [
9‐
15]. However, the role of GAS6-AS1 in CRC remains unclear.
RNA binding proteins (RBPs) play key roles in post transcriptional level by specifically binding to RNAs, affecting the cellular process of cancers [
16]. Fusion in sarcoma/liposarcoma (FUS), as a tumorigenesis-related RBP, which involved in transcription regulation and RNA processing, has been previously reported in multiple cancers, including CRC [
17‐
20].
Here, we reveal that GAS6-AS1 is upregulated in CRC and that elevated GAS6-AS1 expression is associated with unfavorable prognosis in CRC patients. Functional experiments demonstrated that GAS6-AS1 exerts an oncogenic role by promoting CRC growth and metastasis. Mechanistically, GAS6-AS1 promotes CRC tumorigenesis by acting as a competitive endogenous RNA (ceRNA) for miR-370-3p and miR-1296-5p which contributes to TRIM14 upregulation. Furthermore, GAS6-AS1 stabilizes TRIM14 mRNA in an FUS-dependent manner. Thus, we show the clinical significance of GAS6-AS1 in CRC and its underlying mechanism, thereby providing new insights into CRC tumorigenesis.
Materials and methods
Clinical samples
Paired CRC and para-carcinoma samples were obtained from 40 patients who underwent tumor resection at the First Affiliated Hospital of Soochow University (November 2019 to May 2020). Each patient was CRC-positive at diagnosis and had not received preoperative chemoradiotherapy. The age of patients was range from 40 to 75-year-old. Informed consent was obtained from all patients. This study was approved by the ethics committee of the First Affiliated Hospital of Soochow University (No.2019138).
Cell culture
The human CRC cell lines HT29, LoVo, RKO, SW620, the human normal colon epithelial cells (NCM460), and the human embryo kidney cell line HEK-293T were purchased from the Cell Bank of the Chinese Academy of Sciences and the American Type Culture Collection (ATCC). The cells were cultured in RPMI-1640 (Hyclone, USA) or DMEM medium (Hyclone, USA) with 10% fetal bovine serum in a cell incubator at 37 °C and 5% CO2.
Real-time RT-PCR
Total RNA was extracted using a TRIzol reagent kit (Invitrogen, USA). Primers were designed by Sangon Biotech (Shanghai, China) and were listed in Additional file
1: Table S1. Quantitative real-time PCR was conducted with either 2X SYBR Green qPCR Master Mix (Abm, Canada) or miDETECT A Track miRNA qRT-PCR Starter Kit (RiboBio, China). β-actin (for mRNAs and lncRNAs) and U6 (for miRNAs) served as controls.
Subcellular fractionation
The PARIS Kit (Invitrogen, USA) was utilized to extract the cell nuclear and cytoplasmic RNA, for subsequent qRT-PCR. We used β-actin (for cytoplasm) and U6 (for nuclear) for normalizations.
Generation of cell lines with stable overexpression and knockdown of GAS6-AS1
The pCDH-GAS6-AS1, pCDH (blank plasmid), pLenti hU6/shRNA-GAS6-AS1, and pLenti hU6/shRNA-Control was established by Lingke Biotechnology (Shanghai, China). Then, plasmids were transfected into with HEK-293T cells psPAX2 and pMD2G. Virus particles were sterile-filtered, concentrated, and subsequently used for infecting HT29 and LoVo cells to produce corresponding stable cells.
Cell transfection
The miR-370-3p mimics, miR-1296-5p mimics, miR-370-3p inhibitors, miR-1296-5p inhibitors and matched negative controls were synthetized by RiboBio (Guangzhou, China). Small interfering TRIM14 (si-TRIM14, CCA CAT GTG GGT ACT GCA T) were purchased from RiboBio. Lipofectamine 2000 (Invitrogen, USA) was applied for transfection following manufacturer's guide.
Cell proliferation assay
Cells were grown in 96-well plate with 5 × 103 per well. Cell proliferation was detected by Cell Counting Kit (Beyotime, China) after transfected or not. Then the absorbance at 450 nm was measured.
EdU assays
BeyoClick EdU-555 Kits (Beyotime, China) were used for EdU assays. Cells were cultivated in medium containing 10 μM EdU before fixing with 4% paraformaldehyde and subsequent stained with EdU reaction buffer. To visualize the DNA, the cells were stained with Hoechst and observed with fluorescence microscope. The EdU-positive cells were counted.
Scratch healing assay
Cells were seeded into 24-well plates and cultured in the incubator. 10 μl pipette tips were used to scratch on monolayer cells at multiple sites. The area of scratch was observed at 0 h, 24 h and 48 h after scratching. Resulting images were processed with ImageJ software.
Transwell assays
Transwell chambers (Corning, USA) with (migration) and without (invasion) Matrigel (BD Biosciences, USA) were applied to perform transwell assays. Briefly, 1 × 105 cells were cultured in the upper wells with 100 µL serum-free medium. The lower chamber was infused with 600 µL complete medium. After 48 h, the cells on the lower side of the membrane were fixed in 4% paraformaldehyde, stained with 0.1% crystal violet, and quantified under a microscope.
Experimental animals
Animal experiments were conducted following the principles of the Animal Management and Use Committee of Soochow University and approved by the Medical Ethics Committee of The First Affiliated Hospital of Soochow University (Approval No.2017213). 24 BALB/c nude mice (4–5 weeks) were obtained from SLAC Laboratory Animal Center (Shanghai, China) and reared in a specific-pathogen-free environment at 23–25 °C. Xenograft tumors were established by subcutaneously injecting 5 × 106 cells (HT29-GAS6-AS1, HT29-Vector, LoVo-shGAS6-AS1, and LoVo-shControl cells). The tumor size was determined weekly. The mice were euthanized after four weeks, and the tumors were excised and weighed.
For lung metastasis models, 2 × 106 cells (HT29-GAS6-AS1 vs. HT29-Vector, LoVo-shGAS6-AS1 vs. LoVo-shControl) were injected through the tail vein. The mice were euthanized four weeks later. The lung tissue was dissected and fixed with formalin. Lung foci were counted using H&E staining.
RNA fluorescent in situ hybridization
Fluorescent in situ hybridization (FISH) kit (RiboBio, China) was applied for the in-situ detection of GAS6-AS1 in HT29 and LoVo cells following the guidelines. Cells were observed by the fluorescence microscope.
Dual-luciferase reporter assay
For dual-luciferase reporter assays, the wild-type (WT) 3′-UTR of GAS6-AS1/TRIM14 gene containing miR-370-3p and miR-1296-5p binding sites, and the mutant (MUT) 3′-UTR of GAS6-AS1/TRIM14 gene were obtained from RiboBio (Guangzhou, China). The WT/MUT 3′-UTR were co-transfected with mimics or negative control with Lipofectamine 2000 (Invitrogen, USA). Notably, 48 h post-transfection, cells were lysed. Then, we applied the Dual-Luciferase Reporter Assay Kit (Beyotime, China) to evaluate the luciferase activities.
RNA immunoprecipitation (RIP)
RIP was performed using EZ-Magna RIP kits (Millipore, USA). Cells were collected and incubated with anti-Ago2 antibody (Abcam, UK) 24 h after transfection. IgG was used as the negative control. Quantitative RT-PCR was used to assess the co-precipitated RNAs.
Western blot analysis
Here, cells were solubilized in RIPA lysis buffer (Merck, China.). With the BCA method, we standardized the protein concentration. Lysates were resolved by 10–15% SDS polyacrylamide gels and transferred onto PVDF membranes. The membranes were incubated overnight at 4 °C with primary antibodies, including anti-TRIM14 (1:500, Proteintech, USA), anti-GAPDH (1:5000, CST, USA), and anti-E-cadherin (1:1000), anti-N-cadherin (1:1000), anti-Vimentin (1:1000) (Immunoway, USA), followed by another incubation with appropriate secondary antibodies (the anti-rabbit or anti-mouse antibodies were from Immunoway) at 25 °C 2 h. The blots were developed using ECL.
Statistical analysis
All data were analyzed using Prism 7.0 or SPSS24.0. T-test or ANOVA analyses were applied to examine the differences among the groups. P < 0.05 denoted a statistical difference.
Discussion
Compelling evidence indicated that lncRNAs play significant roles in CRC pathogenesis and have great value for CRC diagnosis and treatment [
24,
25]. These abnormal lncRNAs contributed to various behaviors in CRC cells, including proliferation, apoptosis, metastasis, drug resistance, etc. Despite the unclear function of lncRNA GAS6-AS1 in tumors, reports showed that it was significantly elevated in gastric cancer tissues and drived progression of gastric cancer by activating GAS6 [
9]. GAS6-AS1 levels were elevated in hepatocellular carcinoma, thereby promoting disease progression [
10]. Moreover, GAS6-AS1 facilitated breast cancer malignancy via the PI3K/AKT pathway [
11]. GAS6-AS1 is overexpressed in acute myeloid leukemia (AML) and promotes the progression of AML through the YBX1/MYC axis [
15]. Besides, GAS6-AS1 linhibited the progression of lung adenocarcinoma and low GAS6-AS1 levels are associated with poor prognosis of patients [
12‐
14]. However, the role of GAS6-AS1 in CRC has not been explored. This prompted us to examine the effects and potential mechanisms of GAS6-AS1 in CRC.
We first mined and analyzed the TCGA-COAD dataset in the TCGA database, which showed that GAS6-AS1 levels were higher in colon tissues than in normal. GAS6-AS1 expression was positively correlated with unfavorable clinicopathological factors in colon cancer. Further, patients with higher GAS6-AS1 levels had worse prognosis. By examining the GAS6-AS1 levels in 40 pairs of CRC tissues, we verified that the GAS6-AS1 level in CRC tissues was higher than that in adjacent tissues. Functional experiments demonstrated that GAS6-AS1 promoted CRC growth and metastasis in vitro and in vivo. These findings implicated GAS6-AS1 as a pro-tumorigenic lncRNA which involved in tumorigenesis and CRC progression.
ceRNA is an important mechanism by which lncRNAs participate in various cellular processes. Different RNAs sharing the same miRNA response element sequence competitively bind to the same miRNA, thereby forming a complex RNA regulatory network that regulates respective miRNA expression and co-interactions, ultimately influencing biological processes [
26‐
29]. Numerous lncRNAs are associated with tumorigenesis and CRC development through ceRNA mechanisms. For instance, the lncRNA CACS19 promotes CRC progression by binding to miR-140-5p, which consequently upregulates CEMIP [
30]. LncRNA PVT1 promotes CRC progression by sponging miR-30d-5p/miR-45 to regulate RUNX2 [
31,
32]. Moreover, lncRNA CACS15 promotes oxaliplatin resistance in CRC cells by competitively binding to miR-145 and effectively upregulating ABCC1 expression [
33]. The lncRNA TUG1 regulates the resistance of CRC cells to 5-FU by sponging miR-197-3p to upregulate TYMS [
34]. Here, we show that GAS6-AS1 is located in the cytoplasm and nuclei of CRC cells and potentially exerts its function by regulating TRIM14, since it acts as a ceRNA to sponge miR-370-3p/miR-1296-5p.
Although the roles of miR-370-3p and miR-1296-5p in CRC remain unclear, miR-370-3p was found to suppress glioma cell proliferation and induce cell cycle arrest [
35]. Additionally, miR-370-3p impeded bladder cancer cell invasion by suppressing Wnt7a expression, thus inhibited classical Wnt/β-catenin signal transduction and matrix metalloproteinase 10 (MMP10) levels [
36]. MiR-1296-5p has been found to inhibit gastric cancer progression by suppressing CDK6 and EGFR [
37]. Elsewhere, miR-1296-5p inhibited the viability of ERBB2-positive breast cancer cells by targeting the ERB2/mTORC1 pathway [
38] and inhibits osteosarcoma development by targeting Notch [
39]. These findings demonstrated that miR-370-3p and miR-1296-5p may act as antitumor molecules in cancers. Indeed, our results demonstrated that miR-370-3p and miR-1296-5p played a tumor-suppressive role in CRC. We confirmed that the interaction between GAS6-AS1 and miR-370-3p/miR-1296-5p and the pro-tumorigenic effect of GAS6-AS1 in CRC can be partially reversed by overexpressing miR-370-3p/miR-1296-5p.
TRIM14 was predicted as a potential target for miR-370-3p and miR-1296-5p, which was confirmed by luciferase reporter assays. Furthermore, upregulating miR-370-3p or miR-1296-5p decreased TRIM14 levels in CRC cells. Notably, TRIM14 belongs to the tripartite motif (TRIM) family and contributes to various biological processes. A previous report revealed that TRIM14 was highly expressed in a human immunodeficiency virus-related non-Hodgkin's lymphoma [
40]. Additional studies revealed that TRIM14, which was a mitochondrial adapter that promotes innate immune signal transmission, participated in host defenses against viral infection [
41‐
43]. TRIM14 was upregulated during inflammatory stimulation with TNF-α, IL-1β, and LPS, and its overexpression promoted monocyte and endothelial cell adhesion [
43]. Another study found that TRIM14 was a novel regulator of the non-specific NF-κB signaling pathway [
44]. Moreover, TRIM14 expression were found upregulated in gastric cancer [
45]. oral squamous cell carcinoma [
46], tongue cancer [
47], breast cancer [
48], hepatocellular carcinoma [
49], osteosarcoma [
50] and glioma [
51], and function as an oncogene in these cancers. Furthermore, TRIM14 was elevated in CRC tissues and promoted the migration and invasion of CRC cells via the SPHK1/STAT3 pathway [
21]. High TRIM14 expression was closely correlated with poor prognosis of CRC patients, increased cell growth, and inhibited CRC cell apoptosis via the PTEN/Akt pathway [
22]. In this study, we confirmed that GAS6-AS1 could promote CRC progression via GAS6-AS1-miR-370-3p/miR-1296-TRIM14 axis.
An increasing number of studies show that RBPs are involved in the regulation of gene expression by lncRNAs, binding to RBP is one of the main mechanisms by which lncRNAs play a role in the pathological process of cancers [
52]. Here, in addition to the mechanism of acting through ceRNA network, we confirmed that GAS6-AS1 stabilized TRIM14 mRNA through FUS-mediated way, thus further improving the molecular mechanism of GAS6-AS1 facilitating CRC development via mediating TRIM14.
To our knowledge, the present study is the first to report the clinical significance and function of GAS6-AS1 in CRC. Furthermore, functional and mechanistic experiments demonstrated the potential role of GAS6-AS1 as a ceRNA, which involved in accelerating CRC growth and metastasis via sponging miR-370-3p/miR-1296-5p to regulate TRIM14. On the other hand, GAS6-AS1 stabilizes TRIM14 mRNA by recruiting FUS. Therefore, GAS6-AS1 may be a potential biomarker and therapeutic target for CRC treatment. However, our study has some limitations, including analysis using a single dataset and a limited number of collected tissue samples. In future, we will explore the biological functions of GAS6-AS1 in CRC in more detail.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.